Miracle Mile Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Miracle Mile Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-400	Closed	-$1.92K	–	886
2025 Q3	$1.92K	Buy	+400	New	+$2.11K	﹤0.01%	824
2025 Q2	–	Sell	-400	Closed	-$3.7K	–	739
2025 Q1	$3.7K	Hold	400	–	–	﹤0.01%	646
2024 Q4	$8.84K	Buy	+400	New	+$11.3K	﹤0.01%	633

Other funds holding PCSA

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Miracle Mile Advisors's PCSA Position: Q4 2025 in Review

Miracle Mile Advisors sold out of Processa Pharmaceuticals (PCSA) in Q4 2025, closing a stake of 400 shares — an estimated $1.92K sold.

Miracle Mile Advisors first reported a position in PCSA in Q4 2024 and held it in 3 quarters. The position peaked at $8.84K in Q4 2024. 10 funds tracked by Wall St. Rank hold PCSA as of Q4 2025.

Miracle Mile Advisors reported no remaining Processa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Miracle Mile Advisors sold 400 Processa Pharmaceuticals shares in Q4 2025, an estimated $1.92K.
Miracle Mile Advisors first reported a position in Processa Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Miracle Mile Advisors's Processa Pharmaceuticals position peaked at $8.84K in Q4 2024.
10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2025.

Based on Miracle Mile Advisors's 13F filing for Q4 2025, filed 2 Feb 2026.